首页 > 最新文献

Canadian Journal of Kidney Health and Disease最新文献

英文 中文
Multiple Pyoderma Gangrenosum Overlying AV Fistula Treated With Colchicine: A Case Report. 用秋水仙碱治疗覆盖房室瘘的多发性脓皮病:病例报告。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-10-05 eCollection Date: 2024-01-01 DOI: 10.1177/20543581241284749
Alex Derstenfeld, Rosalie-Sélène Meunier, Josée Bouchard, Alexandra Mereniuk

Rationale: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis which gives rise to painful ulcers. Pyoderma gangrenosum can be triggered by trauma, a phenomenon called pathergy. Here, we report the first case of PG arising from pathergy due to needle insertion overlying an arteriovenous fistula (AVF). This case report seeks to inform nephrologists about PG, this yet unreported presentation, and management in the context of hemodialysis.

Presenting concerns: A 69-year-old woman presented to dermatology clinic for erythemato-violaceous plaques with central ulceration at the site of needle insertion overlying her AVF. The patient was known for chronic renal insufficiency secondary to C3 glomerulonephritis, for which she received hemodialysis. After an accidental burn which lead to appearance of a painful ulcer, following each needle insertion for hemodialysis, she would develop an erythematous papule that progressed to a painful ulcer with erythematous-violaceous borders.

Diagnosis: Pyoderma gangrenosum was clinically diagnosed and both clinical and paraclinical evaluation did not reveal any secondary cause of PG.

Intervention: Dialysis via AVF was suspended due to the risk of triggering more PG and was temporarily pursued by central venous catheter. The patient was initially treated with prednisone and topical corticosteroids. Furthermore, owing to the high recurrence rate of PG, colchicine was initiated in prevention to avoid resorting to immunosuppressive or long-term corticotherapy.

Outcomes: The patient's lesions improved on prednisone, which was then tapered over 1 month. Following prednisone taper and continuing improvement of PG on colchicine and topical corticosteroids alone, the decision was taken to recommence dialysis via AVF after performing a negative pathergy test. Topical corticosteroids were ceased due to the risk of cutaneous atrophy and were replaced by pimecrolimus ointment. The patient has continued dialysis via AVF ever since, without recurrence.

Novel finding: This is the first case reported of PG arising from pathergy due to needle insertion overlying an AVF. Colchicine may be a safe and effective therapy for long-term treatment of PG in the context of hemodialysis.

理论依据:坏疽性脓皮病(PG)是一种罕见的嗜中性皮肤病,可引起疼痛性溃疡。脓皮病可由外伤引发,这种现象被称为 "脓疱病"。在此,我们报告了首例因在动静脉瘘(AVF)上方插入针头而引起脓疱疮的病例。本病例报告旨在向肾科医生介绍 PG、这种尚未报道的表现形式以及血液透析时的处理方法:一名 69 岁的女性因在动静脉瘘上方的针插入部位出现红斑、荨麻疹和中心溃疡而到皮肤科就诊。据了解,患者曾因继发于 C3 肾小球肾炎的慢性肾功能不全接受过血液透析治疗。在一次意外烧伤导致出现疼痛性溃疡后,每次插入针头进行血液透析后,她都会出现红斑丘疹,继而发展为疼痛性溃疡,边界红肿:临床诊断为坏疽性脓皮病,临床和辅助临床评估均未发现任何继发性病因:干预措施:由于存在引发更多 PG 的风险,通过 AVF 进行的透析被暂停,暂时通过中心静脉导管进行透析。患者最初接受了泼尼松和局部皮质类固醇治疗。此外,由于 PG 的复发率较高,为了避免采用免疫抑制或长期皮质激素治疗,患者开始使用秋水仙碱进行预防:患者的皮损在使用泼尼松后有所改善,随后在一个月内逐渐减量。泼尼松减量后,仅使用秋水仙碱和外用皮质类固醇激素仍能改善 PG,在进行阴性血凝试验后,决定通过动静脉瘘重新开始透析。由于存在皮肤萎缩的风险,外用皮质类固醇激素被停止使用,取而代之的是吡美莫司软膏。此后,患者一直通过 AVF 进行透析,未再复发:新发现:这是首例因在动静脉瘘上方插入针头而引起脓疱疮的病例。秋水仙碱可能是血液透析中长期治疗 PG 的一种安全有效的疗法。
{"title":"Multiple Pyoderma Gangrenosum Overlying AV Fistula Treated With Colchicine: A Case Report.","authors":"Alex Derstenfeld, Rosalie-Sélène Meunier, Josée Bouchard, Alexandra Mereniuk","doi":"10.1177/20543581241284749","DOIUrl":"10.1177/20543581241284749","url":null,"abstract":"<p><strong>Rationale: </strong>Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis which gives rise to painful ulcers. Pyoderma gangrenosum can be triggered by trauma, a phenomenon called pathergy. Here, we report the first case of PG arising from pathergy due to needle insertion overlying an arteriovenous fistula (AVF). This case report seeks to inform nephrologists about PG, this yet unreported presentation, and management in the context of hemodialysis.</p><p><strong>Presenting concerns: </strong>A 69-year-old woman presented to dermatology clinic for erythemato-violaceous plaques with central ulceration at the site of needle insertion overlying her AVF. The patient was known for chronic renal insufficiency secondary to C3 glomerulonephritis, for which she received hemodialysis. After an accidental burn which lead to appearance of a painful ulcer, following each needle insertion for hemodialysis, she would develop an erythematous papule that progressed to a painful ulcer with erythematous-violaceous borders.</p><p><strong>Diagnosis: </strong>Pyoderma gangrenosum was clinically diagnosed and both clinical and paraclinical evaluation did not reveal any secondary cause of PG.</p><p><strong>Intervention: </strong>Dialysis via AVF was suspended due to the risk of triggering more PG and was temporarily pursued by central venous catheter. The patient was initially treated with prednisone and topical corticosteroids. Furthermore, owing to the high recurrence rate of PG, colchicine was initiated in prevention to avoid resorting to immunosuppressive or long-term corticotherapy.</p><p><strong>Outcomes: </strong>The patient's lesions improved on prednisone, which was then tapered over 1 month. Following prednisone taper and continuing improvement of PG on colchicine and topical corticosteroids alone, the decision was taken to recommence dialysis via AVF after performing a negative pathergy test. Topical corticosteroids were ceased due to the risk of cutaneous atrophy and were replaced by pimecrolimus ointment. The patient has continued dialysis via AVF ever since, without recurrence.</p><p><strong>Novel finding: </strong>This is the first case reported of PG arising from pathergy due to needle insertion overlying an AVF. Colchicine may be a safe and effective therapy for long-term treatment of PG in the context of hemodialysis.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241284749"},"PeriodicalIF":1.6,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cannabis Use, Perspectives, and Experiences Among Patients Receiving Hemodialysis: A Descriptive Patient Survey. 血液透析患者的大麻使用情况、观点和经历:一项描述性患者调查。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-21 eCollection Date: 2024-01-01 DOI: 10.1177/20543581241274002
Josephine Ho, Jennifer Harrison, Marisa Battistella
<p><strong>Background: </strong>Patients with chronic kidney disease experience high burden of symptoms, negatively affecting their quality of life. Medication therapy is often initiated to address these symptoms but is limited by variable efficacy and high pill burden. There is interest among clinicians and patients to explore cannabis and cannabinoids as an alternative treatment to manage symptoms related to kidney disease.</p><p><strong>Objective: </strong>The objectives were to characterize cannabis use among patients receiving maintenance hemodialysis (HD), to describe patient perspectives on cannabis, and to explore patient experiences with their kidney health care team related to cannabis.</p><p><strong>Design: </strong>This was a descriptive, cross-sectional paper-based patient survey.</p><p><strong>Setting/participants: </strong>Patients receiving maintenance HD at Toronto General Hospital in the ambulatory setting between July and August 2020 were included.</p><p><strong>Methods: </strong>A 33-item questionnaire was developed to address the study questions based on existing cannabis questionnaires and input from kidney specialist physicians, pharmacists, kidney nurse practitioners, and patients. The questionnaire was distributed to patients during their in-center HD session. Patients who chose to participate in the study completed the questionnaire and returned it to the study team.</p><p><strong>Results: </strong>In total, there were 52 respondents, of which 11 (21%) reported cannabis use in the preceding 3 months, and 23 (44%) reported historical cannabis use. Baseline characteristics were similar between those who used cannabis and those who did not, with a possible trend of cannabis users being younger. The most commonly reported reasons for using cannabis were recreation and symptom management. Those who reported using cannabis for symptom management were doing so without medical authorization or documentation. Common symptoms that cannabis was used to self-treat were insomnia, anxiety, and/or non-neuropathic pain. Dried flower was the most common type of product used, and smoking was the most common route. Care gaps and opportunities to improve patient care related to cannabis use were identified, related to monitoring and management of adverse effects, management of drug interactions, harm reduction strategies, informed decision-making, and prescriber education.</p><p><strong>Limitations: </strong>The overall participation rate was low, at approximately 17%, possibly related to the COVID-19 pandemic, lack of interest, or fear of revealing cannabis use. Non-response bias is a possible limitation as this was a voluntary survey. The questionnaire was limited to multiple-choice and Likert scale questions, therefore limiting the depth of patient responses.</p><p><strong>Conclusions: </strong>Our study showed that cannabis use among patients receiving HD is common and comparable with the general population. Patients may be using cannab
背景:慢性肾脏病患者症状繁多,对其生活质量造成了负面影响。患者通常会采用药物治疗来缓解这些症状,但由于疗效不一且药片负担较重,药物治疗效果有限。临床医生和患者有兴趣探索将大麻和大麻素作为控制肾病相关症状的替代疗法:目的:了解接受维持性血液透析(HD)的患者使用大麻的情况,描述患者对大麻的看法,并探讨患者与肾脏医疗团队在大麻方面的经验:这是一项描述性横断面纸质患者调查:调查对象包括 2020 年 7 月至 8 月期间在多伦多总医院门诊接受维持性 HD 治疗的患者:根据现有的大麻问卷以及肾脏专科医生、药剂师、肾脏执业护士和患者的意见,针对研究问题制定了一份 33 个项目的问卷。问卷在中心内的血液透析疗程中发放给患者。选择参与研究的患者填写问卷并将其交回研究小组:共有 52 名受访者,其中 11 人(21%)报告在过去 3 个月内吸食过大麻,23 人(44%)报告曾吸食过大麻。吸食大麻者和不吸食大麻者的基线特征相似,吸食大麻者可能呈现年轻化趋势。最常报告的使用大麻的原因是娱乐和控制症状。那些报告使用大麻来控制症状的人是在没有医疗授权或文件的情况下使用大麻的。使用大麻进行自我治疗的常见症状是失眠、焦虑和/或非神经性疼痛。干花是最常用的产品类型,吸食是最常见的途径。研究发现了与大麻使用有关的护理差距和改善患者护理的机会,这些差距和机会涉及不良反应的监测和管理、药物相互作用的管理、减少伤害策略、知情决策和处方教育:总体参与率较低,约为 17%,可能与 COVID-19 大流行、缺乏兴趣或害怕暴露使用大麻的情况有关。由于这是一项自愿性调查,因此可能存在非响应偏差。问卷仅限于多选题和李克特量表问题,因此限制了患者回答的深度:我们的研究表明,接受 HD 治疗的患者吸食大麻的情况很普遍,与普通人群的情况相当。患者可能会在没有医疗团队参与的情况下使用大麻来自我控制与肾病有关的症状。研究发现了改善与大麻使用相关的患者护理的多种机会。
{"title":"Cannabis Use, Perspectives, and Experiences Among Patients Receiving Hemodialysis: A Descriptive Patient Survey.","authors":"Josephine Ho, Jennifer Harrison, Marisa Battistella","doi":"10.1177/20543581241274002","DOIUrl":"10.1177/20543581241274002","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Patients with chronic kidney disease experience high burden of symptoms, negatively affecting their quality of life. Medication therapy is often initiated to address these symptoms but is limited by variable efficacy and high pill burden. There is interest among clinicians and patients to explore cannabis and cannabinoids as an alternative treatment to manage symptoms related to kidney disease.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The objectives were to characterize cannabis use among patients receiving maintenance hemodialysis (HD), to describe patient perspectives on cannabis, and to explore patient experiences with their kidney health care team related to cannabis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;This was a descriptive, cross-sectional paper-based patient survey.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting/participants: &lt;/strong&gt;Patients receiving maintenance HD at Toronto General Hospital in the ambulatory setting between July and August 2020 were included.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A 33-item questionnaire was developed to address the study questions based on existing cannabis questionnaires and input from kidney specialist physicians, pharmacists, kidney nurse practitioners, and patients. The questionnaire was distributed to patients during their in-center HD session. Patients who chose to participate in the study completed the questionnaire and returned it to the study team.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In total, there were 52 respondents, of which 11 (21%) reported cannabis use in the preceding 3 months, and 23 (44%) reported historical cannabis use. Baseline characteristics were similar between those who used cannabis and those who did not, with a possible trend of cannabis users being younger. The most commonly reported reasons for using cannabis were recreation and symptom management. Those who reported using cannabis for symptom management were doing so without medical authorization or documentation. Common symptoms that cannabis was used to self-treat were insomnia, anxiety, and/or non-neuropathic pain. Dried flower was the most common type of product used, and smoking was the most common route. Care gaps and opportunities to improve patient care related to cannabis use were identified, related to monitoring and management of adverse effects, management of drug interactions, harm reduction strategies, informed decision-making, and prescriber education.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;The overall participation rate was low, at approximately 17%, possibly related to the COVID-19 pandemic, lack of interest, or fear of revealing cannabis use. Non-response bias is a possible limitation as this was a voluntary survey. The questionnaire was limited to multiple-choice and Likert scale questions, therefore limiting the depth of patient responses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our study showed that cannabis use among patients receiving HD is common and comparable with the general population. Patients may be using cannab","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241274002"},"PeriodicalIF":1.6,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
End-of-Life Care Among Patients With Kidney Failure on Maintenance Dialysis: A Retrospective Population-Based Study. 维持性透析肾衰竭患者的临终关怀:一项基于人群的回顾性研究。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-21 eCollection Date: 2024-01-01 DOI: 10.1177/20543581241280698
Shuaib Hafid, Sarina R Isenberg, Aleisha Fernandes, Erin Gallagher, Colleen Webber, Meera Joseph, Manish M Sood, Adrianna Bruni, Janet L Davis, Grace Warmels, James Downar, Anastasia Gayowsky, Aaron Jones, Doug Manuel, Peter Tanuseputro, Michelle Howard

Background: Nephrologists routinely provide end-of-life care for patients with kidney failure (KF) on maintenance dialysis. Involvement of primary care and palliative care physicians may enhance this experience.

Objective: The objective was to describe outpatient care patterns in the last year of life and the end-of-life acute care utilization for patients with KF on maintenance dialysis.

Design: Retrospective cohort study using population-level health administrative data.

Setting & participants: Outpatient and inpatient care during the last year of life among patients who died between 2017 and 2019, receiving maintenance dialysis in Ontario, Canada.

Measurements: The primary exposure is patterns of physician specialties providing outpatient care in the last year of life. Outcomes include outpatient encounters in the last year of life, acute care visitation in the last month of life, and place of death.

Methods: We reported the count and percentage of categorical outcomes and the median (interquartile range) for numeric outcomes. We produced time series plots of the mean monthly percentage of encounters to different specialties stratified by physician specialty patterns. We evaluated differences in outcomes by physician specialty patterns using analysis of variance (ANOVA) and Pearson's chi-square tests (P < .05, two-tailed).

Results: Among 6866 patients, the median age at death was 73, 36.1% were female, and 87.8% resided in urban regions. Three patterns emerged: a primary care, nephrology, and palliative care triad (25.5%); a primary care and nephrology dyad (59.3%); and a non-primary care pattern (15.2%). Palliative care involvement is concentrated near death. Of all, 81.4% spent at least 1 day in hospital or emergency department in the last month, but those with primary care, palliative care, and nephrology involvement had the fewest acute care deaths (65.8%).

Limitations: Outpatient care patterns were defined using physician billing codes, potentially missing care from other providers.

Conclusions: Nephrology and primary care predominantly manage outpatient care in the last year of life for patients with KF on maintenance dialysis, with consistent acute care use across care patterns except for the place of death. Future research should explore associations between patterns of care and end-of-life outcomes to identify the most optimal model of care for patients with KF on maintenance dialysis.

背景:肾脏科医生经常为接受维持性透析的肾衰竭(KF)患者提供临终关怀。初级保健和姑息治疗医生的参与可能会改善这种体验:目的:描述维持性透析的肾衰竭患者生命最后一年的门诊护理模式以及临终急症护理的使用情况:设计:使用人群健康管理数据进行回顾性队列研究:2017年至2019年期间在加拿大安大略省接受维持性透析的死亡患者生命最后一年的门诊和住院护理:主要暴露对象是在生命最后一年提供门诊护理的专科医师模式。结果包括生命最后一年的门诊就诊情况、生命最后一个月的急诊就诊情况以及死亡地点:我们报告了分类结果的计数和百分比,以及数字结果的中位数(四分位间距)。我们制作了不同专科每月平均就诊百分比的时间序列图,并按医生专科模式进行了分层。我们使用方差分析(ANOVA)和皮尔森卡方检验(P < .05,双尾)评估了不同专科医生模式的结果差异:在 6866 名患者中,死亡年龄中位数为 73 岁,36.1% 为女性,87.8% 居住在城市地区。出现了三种模式:初级医疗、肾脏内科和姑息治疗三合一(25.5%);初级医疗和肾脏内科二合一(59.3%);以及非初级医疗模式(15.2%)。姑息关怀的参与主要集中在临近死亡时。其中,81.4%的患者在上个月至少在医院或急诊科住院1天,但有初级医疗、姑息治疗和肾内科参与的患者在急诊科死亡的人数最少(65.8%):局限性:门诊护理模式是根据医生账单代码定义的,可能会遗漏其他医疗服务提供者提供的护理:肾脏内科和初级医疗机构主要负责维持性透析的 KF 患者生命最后一年的门诊护理,除死亡地点外,其他护理模式均使用急症护理。未来的研究应探索护理模式与生命末期结果之间的关联,以确定维持性透析的 KF 患者的最佳护理模式。
{"title":"End-of-Life Care Among Patients With Kidney Failure on Maintenance Dialysis: A Retrospective Population-Based Study.","authors":"Shuaib Hafid, Sarina R Isenberg, Aleisha Fernandes, Erin Gallagher, Colleen Webber, Meera Joseph, Manish M Sood, Adrianna Bruni, Janet L Davis, Grace Warmels, James Downar, Anastasia Gayowsky, Aaron Jones, Doug Manuel, Peter Tanuseputro, Michelle Howard","doi":"10.1177/20543581241280698","DOIUrl":"10.1177/20543581241280698","url":null,"abstract":"<p><strong>Background: </strong>Nephrologists routinely provide end-of-life care for patients with kidney failure (KF) on maintenance dialysis. Involvement of primary care and palliative care physicians may enhance this experience.</p><p><strong>Objective: </strong>The objective was to describe outpatient care patterns in the last year of life and the end-of-life acute care utilization for patients with KF on maintenance dialysis.</p><p><strong>Design: </strong>Retrospective cohort study using population-level health administrative data.</p><p><strong>Setting & participants: </strong>Outpatient and inpatient care during the last year of life among patients who died between 2017 and 2019, receiving maintenance dialysis in Ontario, Canada.</p><p><strong>Measurements: </strong>The primary exposure is patterns of physician specialties providing outpatient care in the last year of life. Outcomes include outpatient encounters in the last year of life, acute care visitation in the last month of life, and place of death.</p><p><strong>Methods: </strong>We reported the count and percentage of categorical outcomes and the median (interquartile range) for numeric outcomes. We produced time series plots of the mean monthly percentage of encounters to different specialties stratified by physician specialty patterns. We evaluated differences in outcomes by physician specialty patterns using analysis of variance (ANOVA) and Pearson's chi-square tests (<i>P</i> < .05, two-tailed).</p><p><strong>Results: </strong>Among 6866 patients, the median age at death was 73, 36.1% were female, and 87.8% resided in urban regions. Three patterns emerged: a primary care, nephrology, and palliative care triad (25.5%); a primary care and nephrology dyad (59.3%); and a non-primary care pattern (15.2%). Palliative care involvement is concentrated near death. Of all, 81.4% spent at least 1 day in hospital or emergency department in the last month, but those with primary care, palliative care, and nephrology involvement had the fewest acute care deaths (65.8%).</p><p><strong>Limitations: </strong>Outpatient care patterns were defined using physician billing codes, potentially missing care from other providers.</p><p><strong>Conclusions: </strong>Nephrology and primary care predominantly manage outpatient care in the last year of life for patients with KF on maintenance dialysis, with consistent acute care use across care patterns except for the place of death. Future research should explore associations between patterns of care and end-of-life outcomes to identify the most optimal model of care for patients with KF on maintenance dialysis.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241280698"},"PeriodicalIF":1.6,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics and Practices of High-Performing Centers in Organ Donor Identification and Referral: A Qualitative Study. 高绩效中心在器官捐献者识别和转介方面的特点和做法:定性研究。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-21 eCollection Date: 2024-01-01 DOI: 10.1177/20543581241276362
Leahora Rotteau, Samuel Vaillancourt, Mercedes Magaz, Lisha Lo, Brian M Wong, Jehan Lalani, Sam D Shemie, Samara Zavalkoff
<p><strong>Background: </strong>The identification and referral (ID&R) of potential organ donors to provincial organ donation organizations (ODOs) is a critical first step in the organ donation process. However, even in provinces with mandatory referral legislation, there remains variability in ID&R rates across critical care units, with some units demonstrating high performance despite experiencing similar constraints associated with existing structures, policies, and practices.</p><p><strong>Objective: </strong>We sought to identify the enablers and specific strategies that high-performing critical care units leveraged to achieve their exceptional performance.</p><p><strong>Design: </strong>We conducted a descriptive qualitative study to inform ID&R improvement efforts as part of a positive deviance initiative.</p><p><strong>Setting: </strong>We identified three high-performing critical care units as study sites.</p><p><strong>Participants: </strong>Clinicians working in identified critical care units.</p><p><strong>Methods: </strong>At each site, we interviewed clinical team members about their perceptions and experiences of ID&R. Data analysis followed a thematic analysis approach.</p><p><strong>Results: </strong>We outline three themes describing how the high-performing hospitals achieve strong ID&R practices. First, all units demonstrated a high degree of integration between the concepts of high-quality end-of-life care and organ donation. Team members were consistently notified of successful transplants stemming from their unit, and all missed ID&Rs were tracked and discussed. Second, participants described a team approach with strong medical leadership, where all team members embrace their role in ensuring that no potential donor is missed. Finally, the units adopted strategies to support and simplify ID&R such as collectively simplifying triggers for referral, developing strong working relationships with provincial donor coordinators, and creating informal avenues of communication between clinicians and donor coordinators.</p><p><strong>Limitations: </strong>The lack of comparable data for potential organ donor referral rates across Canada impacted our ability to identify high-performing hospitals based on data. Instead, we contacted the ODOs directly to identify high-performing units that met our criteria. Second, our study sample was limited to three hospital sites from three different provinces and the three hospitals perform organ recovery and transplant on-site.</p><p><strong>Conclusion: </strong>Critical care units can adopt strategies and implement interventions to support ID&R improvement efforts. We provide examples informed by this study. We also highlight considerations that require attention when engaging in this work such as ensuring that all team members are aware of changes in care plans and physicians consistently engage in discussions about organ donation. Local medical leadership is critical to supporting these changes.
背景:向省级器官捐献组织(ODOs)鉴定和转介(ID&R)潜在的器官捐献者是器官捐献过程中至关重要的第一步。然而,即使在制定了强制性转介立法的省份,各重症监护病房的 ID&R 率仍存在差异,一些病房尽管受到与现有结构、政策和实践相关的类似限制,但仍表现出很高的绩效:我们试图找出高绩效重症监护病房实现其卓越绩效的推动因素和具体策略:设计:我们进行了一项描述性定性研究,为作为积极偏差倡议一部分的 ID&R 改进工作提供信息:我们确定了三个表现优异的重症监护病房作为研究地点:方法:在每个研究地点,我们都采访了临床团队成员:在每个研究地点,我们采访了临床团队成员,了解他们对 ID&R 的看法和经验。数据分析采用主题分析法:结果:我们概述了三个主题,描述了高绩效医院如何实现强大的 ID&R 实践。首先,所有单位都展示了高质量临终关怀与器官捐献理念的高度融合。团队成员会持续收到来自本单位的成功移植通知,所有遗漏的ID&R都会被追踪和讨论。其次,与会者描述了一种具有强大医疗领导力的团队方法,在这种方法下,所有团队成员都能发挥自己的作用,确保不遗漏任何潜在的捐献者。最后,这些单位采取了支持和简化 ID&R 的策略,如集体简化转诊的触发因素、与省级捐献协调员建立牢固的工作关系,以及在临床医生和捐献协调员之间建立非正式的沟通渠道:由于缺乏加拿大全国潜在器官捐献者转介率的可比数据,我们无法根据数据确定表现优异的医院。相反,我们直接联系了ODOs,以确定符合我们标准的高绩效单位。其次,我们的研究样本仅限于三个不同省份的三家医院,而且这三家医院都在现场进行器官回收和移植:结论:重症监护病房可以采取策略并实施干预措施,以支持 ID&R 的改进工作。我们根据本研究提供了一些实例。我们还强调了在开展这项工作时需要注意的事项,如确保所有团队成员都了解护理计划的变更,以及医生持续参与有关器官捐献的讨论。地方医疗领导对于支持这些变革至关重要。
{"title":"Characteristics and Practices of High-Performing Centers in Organ Donor Identification and Referral: A Qualitative Study.","authors":"Leahora Rotteau, Samuel Vaillancourt, Mercedes Magaz, Lisha Lo, Brian M Wong, Jehan Lalani, Sam D Shemie, Samara Zavalkoff","doi":"10.1177/20543581241276362","DOIUrl":"10.1177/20543581241276362","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The identification and referral (ID&R) of potential organ donors to provincial organ donation organizations (ODOs) is a critical first step in the organ donation process. However, even in provinces with mandatory referral legislation, there remains variability in ID&R rates across critical care units, with some units demonstrating high performance despite experiencing similar constraints associated with existing structures, policies, and practices.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;We sought to identify the enablers and specific strategies that high-performing critical care units leveraged to achieve their exceptional performance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;We conducted a descriptive qualitative study to inform ID&R improvement efforts as part of a positive deviance initiative.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;We identified three high-performing critical care units as study sites.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;Clinicians working in identified critical care units.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;At each site, we interviewed clinical team members about their perceptions and experiences of ID&R. Data analysis followed a thematic analysis approach.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;We outline three themes describing how the high-performing hospitals achieve strong ID&R practices. First, all units demonstrated a high degree of integration between the concepts of high-quality end-of-life care and organ donation. Team members were consistently notified of successful transplants stemming from their unit, and all missed ID&Rs were tracked and discussed. Second, participants described a team approach with strong medical leadership, where all team members embrace their role in ensuring that no potential donor is missed. Finally, the units adopted strategies to support and simplify ID&R such as collectively simplifying triggers for referral, developing strong working relationships with provincial donor coordinators, and creating informal avenues of communication between clinicians and donor coordinators.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;The lack of comparable data for potential organ donor referral rates across Canada impacted our ability to identify high-performing hospitals based on data. Instead, we contacted the ODOs directly to identify high-performing units that met our criteria. Second, our study sample was limited to three hospital sites from three different provinces and the three hospitals perform organ recovery and transplant on-site.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Critical care units can adopt strategies and implement interventions to support ID&R improvement efforts. We provide examples informed by this study. We also highlight considerations that require attention when engaging in this work such as ensuring that all team members are aware of changes in care plans and physicians consistently engage in discussions about organ donation. Local medical leadership is critical to supporting these changes.","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241276362"},"PeriodicalIF":1.6,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Use of Sucroferric Oxyhydroxide Prior to Sigmoidoscopy in Patients With End-Stage Kidney Disease: A Case Report. 在终末期肾病患者进行乙状结肠镜检查前使用蔗糖铁氧氢氧化物:病例报告。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-12 eCollection Date: 2024-01-01 DOI: 10.1177/20543581241273998
Jennifer Horwitz, Katelyn Roberts, Stephanie Canning, Douglas Mcintosh, Deborah Zimmerman

Rationale: Sucroferric oxyhydroxide is an iron-based phosphate-binding medication that has been approved for the treatment of hyperphosphatemia in patients with end-stage kidney disease. Given the low overall iron release from the polynuclear iron(III)-oxyhydroxide molecule, recommendations regarding its use prior to colonoscopy/sigmoidoscopy have not been developed.

Presenting concerns of the patient: A 51-year-old male with a known history of end-stage renal disease treated with hemodialysis was referred to Gastroenterology for consideration of colonoscopy to rule out malignancy because of a history of rectal bleeding. This was to be completed prior to proceeding with a living-donor kidney transplant.

Diagnoses: Flexible sigmoidoscopy done after non-diagnostic colonoscopy demonstrated diffuse "charcoal-like" material that prevented adequate visualization of the bowel despite standard bowel preparation. The findings were believed to be secondary to the use of sucroferric oxyhydroxide prescribed for hyperphosphatemia.

Interventions: The patient was subsequently instructed to discontinue sucroferric oxyhydroxide for 2 weeks prior to his repeat sigmoidoscopy procedure.

Outcomes: The patient's repeat sigmoidoscopy after discontinuing sucroferric oxyhydroxide allowed for adequate bowel visualization that revealed only a benign lipoma.

Teaching points: This case demonstrates the potential for sucroferric oxyhydroxide use to result in poor bowel preparation and resulting inadequate visualization on lower gastrointestinal endoscopy. It serves to highlight the clinical implications leading to the need for repeated procedures, which contributes to resource waste and unnecessary costs to the healthcare system, as well as delays in diagnostic evaluation required for transplantation; patient frustration was evident.

理由:蔗糖铁氧氢氧化物是一种铁基磷酸盐结合药物,已被批准用于治疗终末期肾病患者的高磷酸盐血症。鉴于多核氢氧化铁(III)分子的总体铁释放量较低,因此尚未制定在结肠镜/乙状结肠镜检查前使用该药物的建议:一名 51 岁的男性患者,已知其有接受血液透析治疗的终末期肾病病史,因有直肠出血病史,转诊至消化内科考虑进行结肠镜检查以排除恶性肿瘤。在进行活体供肾移植之前,必须完成结肠镜检查:诊断:在结肠镜检查未确诊后进行的柔性乙状结肠镜检查显示,尽管进行了标准的肠道准备,但弥漫的 "木炭样 "物质仍阻碍了肠道的充分观察。该结果被认为是继发于使用蔗糖铁氧氢氧化物治疗高磷血症:干预措施:随后指导患者在再次接受乙状结肠镜检查前停用蔗糖铁氧氢氧化物两周:结果:患者在停用蔗糖铁氧氢氧化物后再次接受乙状结肠镜检查,肠道得到充分显影,仅发现一个良性脂肪瘤:本病例表明,使用蔗糖铁氧氢氧化物可能会导致肠道准备不良,从而导致下消化道内窥镜检查视野不足。本病例强调了导致需要重复手术的临床影响,这造成了资源浪费,给医疗系统带来了不必要的成本,并延误了移植所需的诊断评估;患者的沮丧情绪显而易见。
{"title":"The Use of Sucroferric Oxyhydroxide Prior to Sigmoidoscopy in Patients With End-Stage Kidney Disease: A Case Report.","authors":"Jennifer Horwitz, Katelyn Roberts, Stephanie Canning, Douglas Mcintosh, Deborah Zimmerman","doi":"10.1177/20543581241273998","DOIUrl":"https://doi.org/10.1177/20543581241273998","url":null,"abstract":"<p><strong>Rationale: </strong>Sucroferric oxyhydroxide is an iron-based phosphate-binding medication that has been approved for the treatment of hyperphosphatemia in patients with end-stage kidney disease. Given the low overall iron release from the polynuclear iron(III)-oxyhydroxide molecule, recommendations regarding its use prior to colonoscopy/sigmoidoscopy have not been developed.</p><p><strong>Presenting concerns of the patient: </strong>A 51-year-old male with a known history of end-stage renal disease treated with hemodialysis was referred to Gastroenterology for consideration of colonoscopy to rule out malignancy because of a history of rectal bleeding. This was to be completed prior to proceeding with a living-donor kidney transplant.</p><p><strong>Diagnoses: </strong>Flexible sigmoidoscopy done after non-diagnostic colonoscopy demonstrated diffuse \"charcoal-like\" material that prevented adequate visualization of the bowel despite standard bowel preparation. The findings were believed to be secondary to the use of sucroferric oxyhydroxide prescribed for hyperphosphatemia.</p><p><strong>Interventions: </strong>The patient was subsequently instructed to discontinue sucroferric oxyhydroxide for 2 weeks prior to his repeat sigmoidoscopy procedure.</p><p><strong>Outcomes: </strong>The patient's repeat sigmoidoscopy after discontinuing sucroferric oxyhydroxide allowed for adequate bowel visualization that revealed only a benign lipoma.</p><p><strong>Teaching points: </strong>This case demonstrates the potential for sucroferric oxyhydroxide use to result in poor bowel preparation and resulting inadequate visualization on lower gastrointestinal endoscopy. It serves to highlight the clinical implications leading to the need for repeated procedures, which contributes to resource waste and unnecessary costs to the healthcare system, as well as delays in diagnostic evaluation required for transplantation; patient frustration was evident.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241273998"},"PeriodicalIF":1.6,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor in Response to the Article "Clinical Outcomes With Medium Cut-Off Versus High-Flux Hemodialysis Membranes: A Systematic Review and Meta-Analysis". 致编辑的信,回应文章 "中截流与高通量血液透析膜的临床结果:系统回顾与元分析"。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-10 eCollection Date: 2024-01-01 DOI: 10.1177/20543581241278843
Mehmet Riza Altiparmak, Serkan Feyyaz Yalin
{"title":"Letter to the Editor in Response to the Article \"Clinical Outcomes With Medium Cut-Off Versus High-Flux Hemodialysis Membranes: A Systematic Review and Meta-Analysis\".","authors":"Mehmet Riza Altiparmak, Serkan Feyyaz Yalin","doi":"10.1177/20543581241278843","DOIUrl":"https://doi.org/10.1177/20543581241278843","url":null,"abstract":"","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241278843"},"PeriodicalIF":1.6,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11388295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing Subsequent CARdiovascular Medication Reintroduction in the Intensive Care Unit. 优化重症监护病房的后续 CARdiovascular 药物再引入。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-05 eCollection Date: 2024-01-01 DOI: 10.1177/20543581241276361
Hadjer Dahel, Najla Tabbara, Lisa Burry, Gabrielle Hornstein, David Williamson, Han Ting Wang

Importance: Hospital admission for a critical illness episode creates communication breakpoints and can lead to medication discrepancies during hospital stays. Due to the patient's underlying condition and the care setting, chronic medications such as cardiovascular medication are often held, discontinued, or changed to alternative administration routes. Unfortunately, data on the optimal timing of cardiovascular drug reinitiation among intensive care unit (ICU) survivors are lacking.

Objective: The primary objective of this study was to describe the prevalence of chronic cardiovascular medication taken before hospital admission and discontinued at ICU discharge and hospital discharge for critically ill patients. A secondary objective was to assess factors associated with medication discontinuation.

Design setting and participants: We conducted a multicentered retrospective cohort study at 2 tertiary academic hospitals in Canada. All adult patients taking cardiovascular medication before ICU admission and surviving to hospital discharge between April 1, 2016, and April 1, 2017, were eligible.

Main outcomes and measures: The main outcome of the study was the discontinuation of cardiovascular medication prescribed before ICU admission. The outcome was assessed through participants' chart review.

Results: We included 352 patients with a median age of 71.0 years. A total of 155 patients (44.03%) had at least 1 cardiovascular medication discontinued during their stay. Our adjusted model uncovered 3 factors associated with cardiovascular medication discontinuation: male sex (odds ratio [OR] = 0.564, 95% confidence interval [CI] = 0.346-0.919), number of cardiovascular medications taken preadmission (OR = 1.669, 95% CI = 1.003-2.777 for 2 medications and OR = 3.170, 95% CI = 1.325-7.583), and the use of vasopressors (OR = 1.770, 95% CI = 1.045-2.997).

Conclusion: Our study uncovered that cardiovascular medication discontinuation for ICU patients is frequent, especially for renin-angiotensin system (RAS) blockers. Data from our study could be used to reinforce site-specific protocols of medication reconciliation and optimization, as well as inform future protocols aimed at RAS blocker reinitiation follow-up.

重要性:因危重病入院会造成沟通中断,并可能导致住院期间的用药差异。由于患者的基本病情和护理环境,心血管药物等慢性药物通常会被搁置、停用或改用其他给药途径。遗憾的是,有关重症监护室(ICU)幸存者重新开始使用心血管药物的最佳时机的数据还很缺乏:本研究的主要目的是描述重症患者入院前服用的慢性心血管药物在重症监护室出院和出院时停药的情况。次要目标是评估与停药相关的因素:我们在加拿大的两家三级学术医院开展了一项多中心回顾性队列研究。所有在入住 ICU 前服用心血管药物并在 2016 年 4 月 1 日至 2017 年 4 月 1 日期间存活至出院的成年患者均符合条件:研究的主要结果是在入住ICU前停用心血管药物。该结果通过参与者的病历回顾进行评估:我们共纳入了 352 名患者,中位年龄为 71.0 岁。共有 155 名患者(44.03%)在住院期间至少停用了一种心血管药物。我们的调整模型发现了 3 个与心血管药物停用相关的因素:男性(几率比 [OR] = 0.564,95% 置信区间 [CI] = 0.346-0.919)、入院前服用的心血管药物数量(2种药物的OR = 1.669,95% CI = 1.003-2.777;OR = 3.170,95% CI = 1.325-7.583)以及使用血管加压药(OR = 1.770,95% CI = 1.045-2.997):我们的研究发现,重症监护室患者心血管药物的停用很频繁,尤其是肾素-血管紧张素系统(RAS)阻断剂。我们的研究数据可用于加强特定场所的用药调节和优化方案,并为今后旨在重新启用 RAS 阻滞剂的后续方案提供参考。
{"title":"Optimizing Subsequent CARdiovascular Medication Reintroduction in the Intensive Care Unit.","authors":"Hadjer Dahel, Najla Tabbara, Lisa Burry, Gabrielle Hornstein, David Williamson, Han Ting Wang","doi":"10.1177/20543581241276361","DOIUrl":"10.1177/20543581241276361","url":null,"abstract":"<p><strong>Importance: </strong>Hospital admission for a critical illness episode creates communication breakpoints and can lead to medication discrepancies during hospital stays. Due to the patient's underlying condition and the care setting, chronic medications such as cardiovascular medication are often held, discontinued, or changed to alternative administration routes. Unfortunately, data on the optimal timing of cardiovascular drug reinitiation among intensive care unit (ICU) survivors are lacking.</p><p><strong>Objective: </strong>The primary objective of this study was to describe the prevalence of chronic cardiovascular medication taken before hospital admission and discontinued at ICU discharge and hospital discharge for critically ill patients. A secondary objective was to assess factors associated with medication discontinuation.</p><p><strong>Design setting and participants: </strong>We conducted a multicentered retrospective cohort study at 2 tertiary academic hospitals in Canada. All adult patients taking cardiovascular medication before ICU admission and surviving to hospital discharge between April 1, 2016, and April 1, 2017, were eligible.</p><p><strong>Main outcomes and measures: </strong>The main outcome of the study was the discontinuation of cardiovascular medication prescribed before ICU admission. The outcome was assessed through participants' chart review.</p><p><strong>Results: </strong>We included 352 patients with a median age of 71.0 years. A total of 155 patients (44.03%) had at least 1 cardiovascular medication discontinued during their stay. Our adjusted model uncovered 3 factors associated with cardiovascular medication discontinuation: male sex (odds ratio [OR] = 0.564, 95% confidence interval [CI] = 0.346-0.919), number of cardiovascular medications taken preadmission (OR = 1.669, 95% CI = 1.003-2.777 for 2 medications and OR = 3.170, 95% CI = 1.325-7.583), and the use of vasopressors (OR = 1.770, 95% CI = 1.045-2.997).</p><p><strong>Conclusion: </strong>Our study uncovered that cardiovascular medication discontinuation for ICU patients is frequent, especially for renin-angiotensin system (RAS) blockers. Data from our study could be used to reinforce site-specific protocols of medication reconciliation and optimization, as well as inform future protocols aimed at RAS blocker reinitiation follow-up.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241276361"},"PeriodicalIF":1.6,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Five Things to Know About Depression in Hemodialysis. 血液透析患者抑郁的五大注意事项。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-08-27 eCollection Date: 2024-01-01 DOI: 10.1177/20543581241264465
Peter Smylie, Bhanu Prasad
{"title":"Five Things to Know About Depression in Hemodialysis.","authors":"Peter Smylie, Bhanu Prasad","doi":"10.1177/20543581241264465","DOIUrl":"https://doi.org/10.1177/20543581241264465","url":null,"abstract":"","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241264465"},"PeriodicalIF":1.6,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Environmental Scan of Canadian Kidney Transplant Programs for the Management of Patients With Graft Failure: A Research Letter. 加拿大肾移植项目管理移植失败患者的环境扫描:研究报告。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-08-23 eCollection Date: 2024-01-01 DOI: 10.1177/20543581241274006
Anita Slominska, Kathleen Gaudio, M Khaled Shamseddin, Ngan N Lam, Julie Ho, Amanda Vinson, Rahul Mainra, Stephanie Hoar, Marie-Chantal Fortin, S Joseph Kim, Sacha DeSerres, G V Ramesh Prasad, Matthew A Weir, Marcelo Cantarovich, Shaifali Sandal
<p><strong>Background: </strong>Kidney transplant recipients with graft failure (KTR-GF) and those with a failing graft are an increasingly prevalent group of patients. Their clinical management is complex, and outcomes are worse than transplant naïve patients on dialysis. In 2023, the Kidney Disease: Improving Global Outcomes (KDIGO) organization reported findings from a controversies conference and identified several clinical practice priorities for KTR-GF.</p><p><strong>Objective: </strong>As an exercise in needs assessment, we aimed to collate and summarize current practices in adult Canadian kidney transplant programs around these KDIGO-identified clinical practice priorities.</p><p><strong>Design: </strong>Environmental scan followed by content analysis.</p><p><strong>Setting: </strong>Canadian adult kidney transplant programs.</p><p><strong>Measurements: </strong>We categorized the themes of our content analysis around 7 clinical practice priorities: (1) determining prognosis and kidney failure trajectory; (2) immunosuppression management; (3) management of medical complications; (4) preparing for return to dialysis; (5) evaluation and listing for re-transplantation; (6) management of psychological effects; and (7) transition to supportive care.</p><p><strong>Methods: </strong>We solicited documents that identified each program's current care practices for KTR-GF or patients with a failing graft, including policies, procedures, pathways, and protocols. A content analysis of documents and informal correspondence (email or telephone conversations) was done to extract information surrounding the 7 practice priorities.</p><p><strong>Results: </strong>Of the 18 programs contacted, 12 transplant programs participated in this study and a document from a provincial organization (where 2 non-responding programs are located) was procured and included in this analysis. Overall, practice gaps and discrepancies were noted. Many participants highlighted the lack of evidence or consensus to guide the management of KTR-GF as the key reason. Immunosuppression management was the most frequently addressed priority. Six programs and the provincial document recommended a nuanced approach to immunosuppressant management based on clinical factors and re-transplant candidacy. Two programs used the Kidney Failure Risk Equation and eGFR to determine referral trajectories and prepare patients for return to dialysis. Exact processes outlining medical management during the transition were not found except for nephrectomy indications and in 1 program that has a specific transition clinic for KTR-GF. All programs have a formal or informal policy that KTR-GF should be assessed for re-transplantation. Referrals for psychological support and transition to supportive care were made on a case-by-case basis.</p><p><strong>Limitations: </strong>Our environmental scan was at risk of non-response bias and restricted to transplant programs. Kidney clinics and dialysis units may h
背景:移植失败的肾移植受者(KTR-GF)和移植失败的患者越来越多。他们的临床管理非常复杂,治疗效果比接受透析治疗的移植新患者更差。2023 年,肾脏病:改善全球结果(KDIGO)组织报告了一次争议会议的结果,并确定了 KTR-GF 的几个临床实践重点:作为一项需求评估工作,我们旨在围绕 KDIGO 确定的这些临床实践重点,整理和总结加拿大成人肾移植项目的当前实践:设计:环境扫描,然后进行内容分析:环境:加拿大成人肾移植项目:我们围绕7个临床实践重点对内容分析的主题进行了分类:(1)确定预后和肾衰竭轨迹;(2)免疫抑制管理;(3)医疗并发症管理;(4)为恢复透析做准备;(5)再次移植的评估和列表;(6)心理影响管理;(7)向支持性护理过渡:我们征集了一些文件,以确定每个项目目前对 KTR-GF 或移植失败患者的护理措施,包括政策、程序、路径和协议。我们对文件和非正式通信(电子邮件或电话交谈)进行了内容分析,以提取与 7 项优先实践相关的信息:在所联系的 18 个项目中,有 12 个移植项目参与了本研究,另外还从一个省级机构(其中有 2 个项目未做出回应)获得了一份文件,并将其纳入了本分析。总体而言,我们注意到了实践中存在的差距和差异。许多参与者强调,缺乏指导 KTR-GF 管理的证据或共识是主要原因。免疫抑制管理是最常见的优先事项。六项计划和省级文件建议根据临床因素和再移植候选资格对免疫抑制剂管理采取细致入微的方法。两项计划使用肾衰竭风险方程和 eGFR 来确定转诊轨迹,并为患者重返透析治疗做好准备。除了肾切除术适应症和 1 个为 KTR-GF 设立了专门过渡诊所的项目外,没有发现概述过渡期间医疗管理的确切流程。所有项目都有一项正式或非正式的政策,规定应评估 KTR-GF 的再移植情况。心理支持和过渡到支持性护理的转诊是根据具体情况决定的:我们的环境扫描存在无响应偏差的风险,且仅限于移植项目。肾脏诊所和透析室可能有相关的政策和程序,但没有进行检查:我们的环境扫描结果表明了护理方面的不足和潜在的质量改进领域,包括缺乏多学科护理、结构化透析准备和心理支持。此外,还需要优先开展研究,以获得指导 KTR-GF 管理的证据,并为制定临床实践指南的目标做出贡献。
{"title":"An Environmental Scan of Canadian Kidney Transplant Programs for the Management of Patients With Graft Failure: A Research Letter.","authors":"Anita Slominska, Kathleen Gaudio, M Khaled Shamseddin, Ngan N Lam, Julie Ho, Amanda Vinson, Rahul Mainra, Stephanie Hoar, Marie-Chantal Fortin, S Joseph Kim, Sacha DeSerres, G V Ramesh Prasad, Matthew A Weir, Marcelo Cantarovich, Shaifali Sandal","doi":"10.1177/20543581241274006","DOIUrl":"10.1177/20543581241274006","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Kidney transplant recipients with graft failure (KTR-GF) and those with a failing graft are an increasingly prevalent group of patients. Their clinical management is complex, and outcomes are worse than transplant naïve patients on dialysis. In 2023, the Kidney Disease: Improving Global Outcomes (KDIGO) organization reported findings from a controversies conference and identified several clinical practice priorities for KTR-GF.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;As an exercise in needs assessment, we aimed to collate and summarize current practices in adult Canadian kidney transplant programs around these KDIGO-identified clinical practice priorities.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Environmental scan followed by content analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;Canadian adult kidney transplant programs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Measurements: &lt;/strong&gt;We categorized the themes of our content analysis around 7 clinical practice priorities: (1) determining prognosis and kidney failure trajectory; (2) immunosuppression management; (3) management of medical complications; (4) preparing for return to dialysis; (5) evaluation and listing for re-transplantation; (6) management of psychological effects; and (7) transition to supportive care.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We solicited documents that identified each program's current care practices for KTR-GF or patients with a failing graft, including policies, procedures, pathways, and protocols. A content analysis of documents and informal correspondence (email or telephone conversations) was done to extract information surrounding the 7 practice priorities.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of the 18 programs contacted, 12 transplant programs participated in this study and a document from a provincial organization (where 2 non-responding programs are located) was procured and included in this analysis. Overall, practice gaps and discrepancies were noted. Many participants highlighted the lack of evidence or consensus to guide the management of KTR-GF as the key reason. Immunosuppression management was the most frequently addressed priority. Six programs and the provincial document recommended a nuanced approach to immunosuppressant management based on clinical factors and re-transplant candidacy. Two programs used the Kidney Failure Risk Equation and eGFR to determine referral trajectories and prepare patients for return to dialysis. Exact processes outlining medical management during the transition were not found except for nephrectomy indications and in 1 program that has a specific transition clinic for KTR-GF. All programs have a formal or informal policy that KTR-GF should be assessed for re-transplantation. Referrals for psychological support and transition to supportive care were made on a case-by-case basis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;Our environmental scan was at risk of non-response bias and restricted to transplant programs. Kidney clinics and dialysis units may h","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241274006"},"PeriodicalIF":1.6,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Feasibility and Effects of Self-Acupressure on Symptom Burden and Quality of Life in Hemodialysis Patients: A Pilot RCT. 自我压迫对血液透析患者症状负担和生活质量的可行性及影响:试验性 RCT。
IF 1.6 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-08-06 eCollection Date: 2024-01-01 DOI: 10.1177/20543581241267164
Kristen Parker, Shauna Raugust, Becky Vink, Kuljit Parmar, Allan Fradsham, Marni Armstrong

Background: Symptom burden among long-term hemodialysis (HD) patients is high, and addressing symptoms has been identified as a key research priority by patients. Acupressure has shown some effectiveness in management of symptoms in patients with HD.

Objective: The purpose of this study was to explore the feasibility and the effect of implementing a self-administered acupressure intervention on symptom burden and quality of life for in-center HD patients.

Design: A pilot randomized controlled study.

Setting: Two outpatient community HD clinics between in Calgary, Alberta, Canada.

Patients or sample or participants: Patients on HD for at least 3 months and with at least one symptom score rated greater than moderate were eligible for the study.

Methods: Participants were randomized into either the (1) self-acupressure + usual care or (2) usual care alone group. Participants in the acupressure group were given a wooden acupressure tool and taught how to self-administer protocol on 6 acupressure sites for the 4-weeek study duration. Feasibility outcomes were assessed through satisfaction surveys and attrition. Other outcomes included quality of life and symptom scores by validated questionnaires (EQ-5D-5L and Integrated Palliative Outcome Score-Renal [IPOS-Renal]).

Results: Thirty-two participants were successfully enrolled in the study; acceptability was high with study completion at 98% in the intervention group and 82% adherence rate to the 4-week protocol. Participants in the intervention group reported an improved change score in quality of life (EQ-5D-5L Index Score change = +0.053; EQ-5D-5L visual analog scale score change = +6.7). Participants in the intervention group also reported improved symptom scores (IPOS-Renal overall change = -2.8).

Limitations: Small sample size and intervention duration are limitations of this pilot study.

Conclusions: The results from this study suggest that self-acupressure was acceptable and feasible in this sample of HD patients. Self-acupressure may have a role for supporting the management of symptoms in HD patients. These pilot results can be used to inform larger more definitive investigations.

背景:长期血液透析(HD)患者的症状负担很重,解决症状问题已被患者确定为研究的重点。穴位按摩在控制血液透析患者的症状方面有一定的效果:本研究旨在探讨对中心内的 HD 患者实施自我管理的穴位按摩干预对症状负担和生活质量的可行性和影响:设计:试验性随机对照研究:患者或样本或参与者:患者或样本或参与者:接受 HD 治疗至少 3 个月且至少有一项症状评分超过中度的患者有资格参与研究:参与者被随机分为(1)自我穴位按摩+常规护理组或(2)单纯常规护理组。穴位按摩组的参与者将获得一个木制穴位按摩工具,并在为期 4 周的研究期间学习如何在 6 个穴位按摩部位进行自我按摩。可行性结果通过满意度调查和自然减员进行评估。其他结果包括通过有效问卷(EQ-5D-5L 和综合姑息治疗结果评分-肾脏 [IPOS-Renal])得出的生活质量和症状评分:32名参与者成功加入了研究;干预组的研究完成率为98%,4周方案的坚持率为82%,接受度很高。干预组参与者的生活质量得分有所提高(EQ-5D-5L 指数得分变化 = +0.053;EQ-5D-5L 视觉模拟量表得分变化 = +6.7)。干预组参与者的症状评分也有所改善(IPOS-Renal 总体变化 = -2.8):局限性:样本量小和干预持续时间长是这项试点研究的局限性:本研究的结果表明,自我按压在这一 HD 患者样本中是可接受和可行的。自我按压疗法可能有助于缓解 HD 患者的症状。这些试点结果可为更大规模、更明确的调查提供依据。
{"title":"The Feasibility and Effects of Self-Acupressure on Symptom Burden and Quality of Life in Hemodialysis Patients: A Pilot RCT.","authors":"Kristen Parker, Shauna Raugust, Becky Vink, Kuljit Parmar, Allan Fradsham, Marni Armstrong","doi":"10.1177/20543581241267164","DOIUrl":"10.1177/20543581241267164","url":null,"abstract":"<p><strong>Background: </strong>Symptom burden among long-term hemodialysis (HD) patients is high, and addressing symptoms has been identified as a key research priority by patients. Acupressure has shown some effectiveness in management of symptoms in patients with HD.</p><p><strong>Objective: </strong>The purpose of this study was to explore the feasibility and the effect of implementing a self-administered acupressure intervention on symptom burden and quality of life for in-center HD patients.</p><p><strong>Design: </strong>A pilot randomized controlled study.</p><p><strong>Setting: </strong>Two outpatient community HD clinics between in Calgary, Alberta, Canada.</p><p><strong>Patients or sample or participants: </strong>Patients on HD for at least 3 months and with at least one symptom score rated greater than moderate were eligible for the study.</p><p><strong>Methods: </strong>Participants were randomized into either the (1) self-acupressure + usual care or (2) usual care alone group. Participants in the acupressure group were given a wooden acupressure tool and taught how to self-administer protocol on 6 acupressure sites for the 4-weeek study duration. Feasibility outcomes were assessed through satisfaction surveys and attrition. Other outcomes included quality of life and symptom scores by validated questionnaires (EQ-5D-5L and Integrated Palliative Outcome Score-Renal [IPOS-Renal]).</p><p><strong>Results: </strong>Thirty-two participants were successfully enrolled in the study; acceptability was high with study completion at 98% in the intervention group and 82% adherence rate to the 4-week protocol. Participants in the intervention group reported an improved change score in quality of life (EQ-5D-5L Index Score change = +0.053; EQ-5D-5L visual analog scale score change = +6.7). Participants in the intervention group also reported improved symptom scores (IPOS-Renal overall change = -2.8).</p><p><strong>Limitations: </strong>Small sample size and intervention duration are limitations of this pilot study.</p><p><strong>Conclusions: </strong>The results from this study suggest that self-acupressure was acceptable and feasible in this sample of HD patients. Self-acupressure may have a role for supporting the management of symptoms in HD patients. These pilot results can be used to inform larger more definitive investigations.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241267164"},"PeriodicalIF":1.6,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Canadian Journal of Kidney Health and Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1